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Abstract
Introduction: Arthralgias and myalgias are major side effects associated with aromatase inhibitor (AI) therapy of
breast cancer. In a recent genome-wide association study, we identified SNPs - including one that created an
estrogen response element near the 3’ end of the T-cell leukemia 1A (TCL1A) gene - that were associated with
musculoskeletal pain in women on adjuvant AI therapy for breast cancer. We also showed estrogen-dependent,
SNP-modulated variation in TCL1A expression and, in preliminary experiments, showed that TCL1A could induce
IL-17RA expression. In the present study, we set out to determine whether these SNPs might influence cytokine
expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects.
Methods: The functional genomic experiments performed included determinations of TCL1A, cytokine and
cytokine receptor expression in response to estrogen treatment of U2OS cells and lymphoblastoid cell lines that
had been stably transfected with estrogen receptor alpha. Changes in mRNA and protein expression after gene
knockdown and overexpression were also determined, as was NF-B transcriptional activity.
Results: Estradiol (E2) increased TCL1A expression and, in a TCL1A SNP-dependent fashion, also altered the
expression of IL-17, IL-17RA, IL-12, IL-12RB2 and IL-1R2. TCL1A expression was higher in E2-treated lymphoblastoid
cell lines with variant SNP genotypes, and induction of the expression of cytokine and cytokine receptor genes was
mediated by TCL1A. Finally, estrogen receptor alpha blockade with ICI-182,780 in the presence of E2 resulted in
greatly increased NF-B transcriptional activity, but only in cells that carried variant SNP genotypes. These results
linked variant TCL1A SNP sequences that are associated with AI-dependent musculoskeletal pain with increased
E2-dependent TCL1A expression and with downstream alterations in cytokine and cytokine receptor expression as
well as NF-B transcriptional activity.
Conclusions: SNPs near the 3’ terminus of TCL1A were associated with AI-dependent musculoskeletal pain. E2
induced SNP-dependent TCL1A expression, which in turn altered IL-17, IL-17RA, IL-12, IL-12RB2, and IL-1R2
expression as well as NF-B transcriptional activity. These results provide a pharmacogenomic explanation for a
clinically important adverse drug reaction as well as insights into a novel estrogen-dependent mechanism for the
modulation of cytokine and cytokine receptor expression.
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The introduction of aromatase inhibitors (AIs), drugs
that block the enzyme that synthesizes estrogens, to treat
women with estrogen receptor (ER)-positive breast can-
cer marked a significant advance in the treatment of this
disease, with a reduction in recurrence of approximately
50% [1]. However, AI therapy can also result in drug-
induced musculoskeletal pain as a major side effect that
can result in the termination of AI therapy [2]. For exam-
ple, in the Arimidex, Tamoxifen, Alone or in Combina-
tion breast cancer clinical trial, up to 28% of women
treated with AIs developed musculoskeletal pain, and
approximately 10% discontinued therapy because of this
adverse drug reaction [3]. Changes in circulating estrogen
levels in women have long been associated with muscu-
loskeletal symptoms. Arthritis of the menopause was
described by Cecil and Archer over 85 years ago [4], and
joint pain was a major complaint among participants in
the Women’s Health Initiative study after the withdrawal
of estrogen therapy [5].
We recently performed a case-control genome-wide
association study (GWAS) of participants in the NCIC-
CTG MA.27 clinical trial of AI adjuvant therapy in post-
menopausal women with ER-positive breast cancer in an
attempt to identify biomarkers and define mechanisms
responsible for musculoskeletal pain associated with
pharmacologic blockade of estrogen synthesis. That
GWAS identified a SNP signal on chromosome 14 that
mapped near the 3’ end of the T-cell leukemia 1A
(TCL1A) gene [6], and the SNP with the lowest P value
(rs11849538, P =6 . 6 7×1 0
-7) created a functional estro-
gen response element (ERE). We also observed that
TCL1A expression was induced by estrogen exposure,
and that it was significantly elevated in lymphoblastoid
cell lines (LCLs) that carried variant sequences for the
chromosome-14 SNPs; that is, in cell lines with DNA
encoding the SNP-related ERE. The present study was
performed to pursue possible mechanisms by which
these SNPs might be associated with musculoskeletal
pain in response to reduced estrogen levels during AI
therapy, mechanisms that might also have broader impli-
cations for the role of estrogens in musculoskeletal pain
[6].
TCL1A is a member of a TCL1 family of proteins that
includes TCL1A, TCL1B and TCL6 [7]. This protein is
expressed in activated T lymphocytes and B lympho-
cytes as well as thymocytes, can interact with Akt and
can enhance Akt kinase activity [8-11], but little is
otherwise known about TCL1A function. In follow-up
of our original GWAS, we reported that TCL1A expres-
sion was estrogen dependent and was correlated with
expression of the cytokine receptor IL-17RA [6]. In the
present study, we set out to determine whether TCL1A
expression - expression that is estrogen dependent but
is altered by the SNPs that were associated with AI-in-
duced musculoskeletal pain - might also be associated
with variation in the expression of other cytokines and/
or cytokine receptors. Many of the experiments
described subsequently were performed with U2OS cells
because those cells express TCL1A and have been stably
transfected with ERa, and with a powerful genomic
data-rich LCL model system that includes cell lines with
known TCL1A SNP genotypes. The availability of these
LCLs, also stably transfected with ERa, made it possible
for us to link the SNPs that we observed during the
clinical GWAS for AI-induced musculoskeletal pain
with variation in the expression of a series of cytokine
and cytokine receptor genes that have been implicated
in arthritis. Specifically, we observed, as described in
detail subsequently, that estrogen-dependent, SNP-
modulated expression of TCL1A is not only associated
with variation in IL-17RA expression but also with the
expression of IL-17, IL-1R2, IL-12 and IL-12RB2 as well
as variation in NF-B transcriptional activity.
Materials and methods
Human Variation Panel lymphoblastoid cell lines
The Human Variation Panel of LCLs from 100 healthy
European-American, 100 African-American and 100 Han
Chinese-American subjects was obtained from the Coriell
Institute (Camden, NJ, USA). These cell lines were gener-
ated from blood samples obtained by the National Insti-
tute of General Medical Sciences. We genotyped DNA
from these cell lines for genome-wide SNPs using the Illu-
mina 550K and 510S SNP BeadChip (Illumina, San Diego,
CA, USA). The Coriell Institute also genotyped DNA from
the same cell lines using the Affymetrix SNP Array 6.0
(Affymetrix, Santa Clara, CA, USA) for a total of ~1.3 mil-
lion unique SNPs per cell line [12]. We also generated
basal Affymetrix U133 2.0 Plus GeneChip expression array
data for all of the cell lines. This LCL genomic model sys-
tem has been described in detail elsewhere [12]. The
microarray data and SNP data for these LCLs have been
deposited in the NCBI Gene Expression Omnibus [13]
under SuerSeries [GEO:GSE24277].
Lymphoblastoid cell line transfection and culture
Three of the European-American Human Variation
Panel LCLs with variant genotypes for the chromosome-
14 SNPs rs7158782, rs7159713, rs2369049 and
rs11849538, and three with wild type (WT) sequences
were stably transfected with a pcDNA4.1-ERa construct
provided by Dr Thomas Spelsberg (Mayo Clinic, Roche-
ster, MN, USA). Genotypes for the rs11849538 SNP in
the cell lines were confirmed by performing the PCR
with genomic DNA as the template using the following
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Page 2 of 11primers: forward, 5’-GTGACAAGAAAGCTGTGGAC-
TAGAGACACA-3’;a n dr e v e r s e ,5 ’-TTGGAGGCA-
TACGTTGAGAACCATTGGAGTAA-3’. Genotypes for
the other three chromosome-14 SNPs in these cells had
been determined during GWAS genotyping. These six
stably transfected LCLs were cultured with or without
estradiol (E2), as described previously [6]. In some
experiments, the ERa inhibitor ICI-182,780 (Tocris,
Baldwin, MO, USA) was added to culture medium con-
taining 0.01 nM E2 for an additional 24 hours after the
initial 24 hours at final E2 concentrations of 10
-10,1 0
-9,
10
-8 and 10
-7 μM, and total RNA was isolated from the
cells with the RNeasy mini kit (Qiagen, Valencia, CA,
USA). Two hundred nanograms of this RNA was then
used to perform quantitative RT-PCR with appropriate
primers. Expression levels were normalized on the basis
of ERa expression in each cell line.
NF-B transcriptional activity
U2OS-ERa cells [14] were seeded in triplicate in 12-well
cell culture plates, with 10
5 cells/well. After 24 hours,
the cells were transfected using Lipofectamine 2000
(Invitrogen, Grand Island, NY, USA) with two plasmids;
one encoding an NF-B promoter-luciferase construct
(SABioscience, Foster City, CA, USA), and the other
encoding a Renilla luciferase vector (Promega, Madison,
WI, USA). Co-transfection with the Renilla construct
made it possible to correct for possible variation in
transfection efficiency. Transfected cells were incubated
overnight and were then grown for 24 hours in DMEM
with 5% charcoal-stripped FBS, followed by incubation
in DMEM without FBS for 24 hours, either with ethanol
or with 0.1 nM E2 dissolved in ethanol. The cells were
then harvested and analyzed for luciferase activity
(Promega).
The six LCLs with differing genotypes for the four
chromosome-14 SNPs that had been stably transfected
with ERa were also transiently transfected with 2 μgN F -
B reporter plasmid and 500 ng Renilla luciferase or 2 μg
empty reporter plasmid plus 500 ng Renilla luciferase
construct. Specifically, 2 × 10
6 cells were suspended in
Cell Line Nucleofector Kit V solution (Lonza, Cologne,
Germany) with 2 μg purified NF-B reporter plasmid
and 500 ng Renilla reporter plasmid, and were electropo-
rated with the T-030 program using the Amaxa Nucleo-
fector II (Amaxa Biosystems, Gaithersburg, MD, USA).
Cells from six electroporation procedures per LCL were
pooled to obtain 1.2 × 10
7 cells. Electroporated cells were
then plated in RPMI 1640 medium supplemented with
15% FBS, were allowed to recover from electroporation
for 24 hours, and were cultured for 24 hours in RPMI
1640 media containing 5% (vol/vol) charcoal-stripped
FBS, followed by incubation for 24 hours in the same
media containing increasing concentrations of E2. At
that time, cells treated with 0.01 nM E2 were exposed to
increasing concentrations of ICI-182,780 for a final
24 hours. Luciferase assays were performed, and those
values were corrected for possible variation in transfec-
tion efficiency by use of the Renilla luciferase values.
Western blot analysis
Proteins were isolated from U2OS-ERa cells after lysis
with CelLytic M Cell Lysis buffer (Sigma-Aldrich, St.
Louis, MO, USA) and were subjected to electrophoresis
on 15% SDS-PAGE gels, followed by transfer to polyvinyli-
dene fluoride membranes. The polyvinylidene fluoride
membranes were probed with appropriate antibodies, and
protein bands were visualized using enhanced chemilumi-
nescence (Thermo Scientific, Rockford, IL, USA).
Results
NCIC-CTG MA.27 genome-wide association study
A brief description of the MA.27 breast cancer clinical
trial GWAS is necessary prior to describing the functional
implications of the chromosome-14 SNPs that were asso-
ciated with musculoskeletal pain during that study. MA.27
is a large adjuvant AI clinical trial of patients with postme-
nopausal ER-positive breast cancer who were treated with
one of two AIs, anastrozole or exemestane. There was no
difference between the two drugs in breast cancer recur-
rence [15,16]. For both drugs, however, the primary reason
for discontinuing drug therapy was the occurrence of mus-
culoskeletal pain. We genotyped DNA samples from
women enrolled in the MA.27 trial in an attempt to iden-
tify SNPs associated with musculoskeletal pain after AI
therapy [17].
The three GWAS SNPs with the lowest P values
(rs7158782, rs7159713 and rs2369049) mapped to chro-
mosome 14, and imputation followed by genotyping
showed that one of the imputed SNPs (rs11849538) had
an even lower P value (P = 6.67 × 10
-7; odds ratio = 2.21)
than the SNPs genotyped using the GWAS platform. All
four of the SNPs with the lowest P values were in linkage
disequilibrium, and all four mapped close to TCL1A, with
rs11849538 (the imputed SNP with the lowest P value)
located only 926 base pairs 3’ to the TCL1A gene [6]. That
SNP created a functional ERE. We also reported that
estrogens induced TCL1A expression; that estrogen induc-
tion of TCL1A expression was significantly greater in
LCLs that carried variant rather than WT SNP genotypes;
and, finally, that TCL1A appeared to upregulate expres-
sion of the cytokine receptor gene IL-17RA. The present
study was designed to move beyond these initial, prelimin-
ary functional observations. The results described subse-
quently link variation in estrogen-dependent TCL1A
expression to variation in the expression of a series of
genes encoding cytokines and cytokine receptors that are
known to play a role in musculoskeletal pathophysiology,
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TCLIA-mediated mechanism for the regulation of cyto-
kine expression that was uncovered by exposure to AI
therapy.
SNP-dependent regulation of TCL1A, IL-17RA, IL-17,
IL-1R2, IL-12 and IL-12RB2 expression
As a first step in studying the possible relationship of
the SNPs near TCL1A with the expression of cytokines
and cytokine receptors, we took advantage of the
Human Variation Panel LCL model system to ask
whether variation in TCL1A mRNA expression might
be associated with variation in cytokine or cytokine
receptor expression in these cells. It was important that
we use this cell system because genome-wide genotypes
were known for all of these LCLs, so they could be used
to evaluate the effect of the SNPs discovered during the
clinical GWAS. There was a significant correlation
between TCL1A expression and those of a series of
cytokine receptor genes in the 300 cell lines included in
this model system. All of the correlations of cytokine
receptor expression with expression of TCL1A that had
P ≤ 10
-9 in the Human Variation Panel are listed in
Table 1.
We next determined the effect of estrogen-dependent
TCL1A expression in LCLs with variant or WT chro-
mosome-14 SNPs on the expression of these cytokine
receptors and their ligands. Specifically, we tested the
possible relationship of change in TCL1A expression in
response to increasing concentrations of E2 with those
for all of the cytokine receptors listed in Table 1 as well
as their ligands. We found that the expression of
TCL1A, IL-17RA, IL-17, IL-1R2, IL-12RB2 and IL-12
were all significantly altered in a SNP-dependent fashion
by exposure of LCLs with known genotypes for the
chromosome-14 SNPs to increasing concentrations of
E2 (Figure 1). Specifically, there was increased expres-
sion of both TCL1A and IL-17RA in cells with variant
SNP genotypes. In contrast, there was greater expression
in cells with WT than in those with variant SNP alleles
for IL-17, IL-12, IL-1R2 and IL-12RB2. These differ-
ences were confirmed and explored in the course of
subsequent experiments. Furthermore, as described
subsequently, knockdown or overexpression of TCL1A
also demonstrated that TCL1A induction was upstream
of changes in cytokine receptor or cytokine gene
expression.
TCL1A knockdown and overexpression
To determine whether correlations between the expres-
sion of TCL1A and those of cytokines and cytokine
receptors shown in Figure 1 might represent a causal
relationship, we next knocked down and overexpressed
TCL1A and tested the effect on the expression of
IL-17RA, IL-17, IL-1R2, IL-12 and IL-12RB2. Initially, we
tested IL-17RA and IL-17 by performing quantitative
RT-PCR and western blot analyses after TCL1A knock-
down or overexpression. Those experiments were per-
formed using U2OS-ERa cell lines because these cells
express TCL1A - making it possible to determine the
effect of knockdown - and also because they are stably
transfected with ERa, making it possible to test the effect
of estrogen exposure. Knockdown was performed with
four different TCL1A siRNAs (Qiagen, Valencia, CA,
USA), resulting in significantly decreased IL-17RA
mRNA expression for all four siRNAs tested, with either
no change or a significant increase in IL-17 expression
(Figure 2A). Overexpression of TCL1A resulted in
increased IL-17RA mRNA expression and significantly
decreased expression of IL-17 (Figure 2C). Results
of western blot analysis paralleled the mRNA changes
(Figure 2B, D).
Having observed that TCL1A and IL-17RA were upre-
gulated by E2 (Figure 1), we wanted to determine
whether E2 upregulated TCL1Aa n dI L - 1 7 R Ai np a r a l l e l
or in series; that is, whether TCL1A was upstream of
IL-17RA - as suggested by the effect of the SNPs on
estrogen-dependent cytokinee x p r e s s i o n( F i g u r e1 ) .T o
test the hypothesis that TCL1A might be upstream of
cytokine expression, we knocked down TCL1A using the
same four siRNAs used to perform the experiments
shown in Figure 2A, with or without the addition of 0.1
nM E2, and then assayed both TCL1A and IL-17RA
mRNA expression by quantitative RT-PCR. When
TCL1A was knocked down, IL-17RA expression also
decreased (shown in Figure 3A). Furthermore, when 0.1
nM E2 was added after TCL1A knockdown, IL-17RA
mRNA expression was no different from that observed in
the absence of estrogen (Figure 3B) - indicating that E2
did not directly increase IL-17RA expression, but rather
that TCL1A was upstream of IL-17RA.
To determine whether the other cytokines and cytokine
receptors shown in Figure 1 behaved in a similar fashion,
we knocked down and overexpressed TCL1A and per-
formed quantitative RT-PCR, as we had for IL-17RA.
When we knocked down TCL1A using an siRNA pool
(Dharmacon, Lafayette, CA, USA), either with or without
Table 1 Correlation of T-cell leukemia 1A expression with
cytokine receptor expression in lymphoblastoid cell lines
Gene Gene name P value Spearman r
IL-13RA1 IL-13 receptor, alpha 1 3.16 × 10
-14 -0.428
IL-18R1 IL-18 receptor 1 2.77 × 10
-13 -0.409
IL-1R2 IL-1 receptor, type 2 1.73 × 10
-11 -0.384
IL-17RA IL-17 receptor A 1.92 × 10
-10 0.365
IL-12RB2 IL-12 receptor, beta 2 4.84 × 10
–9 -0.337
Correlation of T-cell leukemia 1A expression with cytokine receptor expression
in 300 lymphoblastoid cell lines from subjects of three different ethnicities.
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Page 4 of 1124 hours of exposure to 0.1 nM E2, TCL1A knockdown
resulted in significant increases in IL-12, IL-12RB2 and
IL-1R2 mRNA expression (Figure 4A). Furthermore,
after TCL1A knockdown, addition of 0.1 nM E2 did not
change the expression of these cytokines and cytokine
receptors beyond that seen with TCL1A knockdown
alone (Figure 4A), exactly as we had observed for IL-
17RA. Conversely, overexpression of TCL1A resulted in
a 24% decrease in IL-12, a 58% decrease in IL-12RB2 and
a 13% decrease in IL-1R2 mRNA expression in the same
cells (Figure 4B). These results were compatible with the
conclusion that E2 upregulates TCL1A expression and
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Figure 1 Effect of estradiol concentration on mRNA expression for cytokine receptors in lymphoblastoid cell line SNPs. Effect of
estradiol (E2) concentration on mRNA expression for (A) T-cell leukemia 1A (TCL1A), (B) IL-17RA, (C) IL-17, (D) IL-12RB2, (E) IL-12 and (F) IL-1R2
in Human Variation Panel lymphoblastoid cell lines with wild type (WT) (n = 3) or variant (V) (n = 3) SNP sequences. *P < 0.05 and **P < 0.001
compared with zero E2,
+P < 0.05 and
++P < 0.01 for differences between WT and V SNP genotypes at the same E2 concentrations.
Liu et al. Breast Cancer Research 2012, 14:R41
http://breast-cancer-research.com/content/14/2/R41
Page 5 of 11Figure 2 T-cell leukemia 1A knockdown and overexpression and IL-17RA and IL-17 expression. (A) Relative T-cell leukemia 1A (TCL1A), IL-
17RA and IL-17 mRNA expression levels in U2OS-estrogen receptor alpha (ERa) cells after TCL1A was knocked down using four different specific
siRNAs. (B) Western blots of TCL1A, IL-17RA, IL-17 and b-actin, with or without TCL1A knockdown in U2OS-ERa cells. (C) Relative TCL1A, IL-17RA
and IL-17 mRNA expression levels after TCL1A overexpression (OE) in U2OS-ERa cells. (D) Western blots of TCL1A, IL-17RA, IL-17 and b-actin, with
or without TCL1A overexpression in U2OS-ERa cells. All data are the mean ± standard error of the mean of triplicate determinations.
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Figure 3 Estradiol upregulates T-cell leukemia 1A and IL-17RA in series. (A) T-cell leukemia 1A (TCL1A) and IL-17RA expression after TCL1A
was knocked down in U2OS-estrogen receptor alpha (ERa) cells by four different TCL1A-specific siRNAs and by a pool of the four siRNAs. (B)
TCL1A and IL-17RA expression after TCL1A was knocked down by four different TCL1A-specific siRNAs and a pool of the four siRNAs with an
additional 24 hours exposure to 0.1 nM estradiol (E2). All values represent the mean ± standard error of the mean of triplicate determinations.
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Page 6 of 11that TCL1A upregulation then increases IL-17RA expres-
sion, but results in decreased IL-12, IL-12RB2 and IL-1R2
expression in this cell line (depicted schematically in
Figure 4C). However, even though this series of experi-
ments indicated that TCL1A, in a SNP-dependent fash-
ion, could mediate E2-dependent regulation of the
expression of selected cytokine receptors and cytokines,
they did not clearly explain how reduced estrogen con-
centrations might result in inflammation or musculoske-
letal pain. We therefore also determined whether TCL1A
might influence the transcriptional activity of NF-B, a
known mediator of joint inflammation [18].
TCL1A downregulation of NF-B transcriptional activity
NF-B is activated in the joints of patients with many
rheumatologic diseases [19], and IL-17 is known to influ-
ence NF-B transcriptional activity [20]. TCL1A is an Akt
co-activator [21], and activation of the phosphoinositide 3-
kinase/Akt pathway negatively regulates NF-B [22]. An
effect of TCL1A on NF-B could therefore potentially
contribute to the relationship of TCL1A to musculoskele-
tal pain in patients treated with AIs, so we attempted to
determine whether TCL1A might alter NF-B transcrip-
tional activity. NF-B proteins are sequestered in the cell
by binding to a family of inhibitory IB proteins [23]. A
variety of stimuli, including many cytokines, can lead to
IB phosphorylation catalyzed by IKK [24].
To determine whether TCL1A might influence NF-B
transcriptional activity, we transfected U2OS-ERa cells
with an NF-B reporter construct. TCL1A knockdown in
those cells to 22% of baseline (Figure 5A) increased NF-B
transcriptional activity by 5.7-fold (Figure 5B). When the
cells were incubated for 24 hours with 0.1 nM E2, how-
ever, TCL1A mRNA increased 6.9-fold and NF-B activity
decreased to 38% of the value after exposure to negative
siRNA. Incubation with 0.1 nM E2 after knockdown of
TCL1A resulted in TCL1A mRNA levels that were 56% of
those after negative siRNA treatment (Figure 5A), while
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Figure 4 Estradiol upregulates T-cell leukemia 1A upstream of IL-12, IL-12RB2 and IL-1R2. (A) T-cell leukemia 1A (TCL1A), IL-12, IL-12RB2
and IL-1R2 expression in U2OS-estrogen receptor alpha (ERa) cells after TCL1A was knocked down (KD) by an siRNA pool, with or without
subsequent exposure to 0.1 nM estradiol (E2) for 24 hours. (B) TCL1A, IL-12, IL-12RB2 and IL-1R2 expression in U2OS-ERa cells after TCL1A
overexpression (OE). All values are the mean ± standard error of the mean of triplicate determinations. (C) Diagrammatic representation of the
sequential E2 upregulation of TCL1A followed by altered cytokine or cytokine receptor expression.
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Page 7 of 11NF-B activity in the same cells increased threefold (Fig-
ure 5B). Western blot analysis confirmed these results as
well as the association of these alterations in TCL1A
expression with those of phosphorylated IB in the same
cells (Figure 5C). These results suggested that a decrease
in TCL1A expression after estrogen withdrawal (for exam-
ple, after treatment with ER antagonists or AIs) might
increase NF-B transcriptional activity. The next experi-
ment was performed in an effect to determine the effect of
increasing concentrations of E2 or of E2 withdrawal on
NF-B transcriptional activity, as well as the effect of the
chromosome-14 SNPs near TCL1A on the response to
those changes in estrogen effect.
TCL1A SNPs, estrogen-dependent TCL1A expression and
NF-B activity
To determine the effect of the SNPs near TCL1A on
estrogen withdrawal and on NF-B transcriptional
activity, we treated Human Variation Panel LCLs - three
with WT SNP genotypes and three with variant SNP gen-
otypes, all stably transfected with ERa - with low concen-
trations of estrogen, followed by ER blockade to replicate
the estrogen withdrawal thato c c u r sd u r i n gA It h e r a p y .
Specifically, these six LCLs were treated with increasing
concentrations of E2, followed by blockade of the ER
with ICI-182,780 [14], still in the presence of 0.01 nM
E2. The quantitative RT-PCR and NF-B reporter assays
were then performed to determine whether the SNPs
might influence estrogen-dependent TCL1A expression
and/or NF-B transcriptional activity.
When the LCLs were treated with increasing concen-
trations of E2 (0.00001 to 0.01 nM), concentrations
similar to those found in the plasma of postmenopausal
women [25], average TCL1A expression increased
approximately five fold in LCLs with variant SNP geno-
types (Figure 6A). In the three cell lines with the WT
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Figure 5 T-cell leukemia 1A knockdown and NF-B transcriptional activity. (A) T-cell leukemia 1A (TCL1A) expression in U2OS-estrogen
receptor alpha (ERa) cells before and after siRNA knockdown (KD), with or without the addition of 0.1 nM estradiol (E2) for an additional 24
hours. (B) NF-B transcriptional activity after co-transfection with an NF-B reporter construct together with TCL1A-negative siRNA or TCL1A-
specific siRNA. Forty-eight hours after transfection, the cells were exposed to 0.1 nM E2 for an additional 24 hours. All values are the mean ±
standard error of the mean of triplicate determinations. (C) Western blots for TCL1A, phosphorylated IB, IB and actin after TCL1A knockdown
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Page 8 of 11genotype, however, average TCL1A expression increased
only approximately 40%, as expected on the basis of our
previous results as shown in Figure 1[6]. To determine
the effect of ER blockade in this setting, increasing con-
centrations (from 10
-10 to 10
-7 μM) of the ER antago-
n i s t ,I C I - 1 8 2 , 7 8 0 ,w e r et h e na d d e dt ot h ec e l l si nt h e
presence of 0.01 nM E2. TCL1A expression in cells with
the variant genotype decreased to levels well below
baseline, while expression in cells with WT genotypes
continued to increase to approximately 3.5-fold those of
baseline (Figure 6A).
To determine whether the change in TCL1A expres-
sion that occurred in response to ER blockade might
influence NF-B transcriptional activity, NF-B reporter
gene assays were performed (Figure 6B) with the same
samples shown in Figure 6A. NF-B transcriptional
activity did not differ greatly (from 70 to 100% of base-
line) between cells with WT and variant genotypes as
E2 concentrations increased from 0.00001 to 0.01 nM.
In cells with variant SNP genotypes, however, the
NF-B activity rose over three fold when the ERa
antagonist was added. This behavior contrasted with
that of cell lines with the WT genotype, in which NF-
B activity decreased slightly (Figure 6B). The ICI-
182,780 blockade of ERa therefore resulted in increased
TCL1A-mediated stimulation of NF-B transcriptional
activity in cells with variant SNP genotypes, in contrast
to the situation seen for cell lines with WT genotypes.
This increase in NF-B transcriptional activity after
estrogen withdrawal may contribute to increased risk for
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Figure 6 SNP-related variation in T-cell leukemia 1A expression and NF-B activity in lymphoblastoid cell lines. SNP-related variation in
T-cell leukemia 1A (TCL1A) expression and NF-B transcriptional activity in three lymphoblastoid cell lines (LCLs) with variant (V) genotypes and
three LCLs with wild type (WT) genotypes for the chromosome-14 SNPs after exposure to increasing concentrations of estradiol (E2), or E2 plus
the estrogen receptor (ER) antagonist ICI-182,780. (A) Quantitative RT-PCR of TCL1A expression after exposure to increasing concentrations of E2
for 24 hours, followed by 0.01 nM E2 plus increasing concentrations of ICI-182,780 for an additional 24 hours. (B) The same six LCLs were
transfected with an NF-B reporter construct. After exposure to increasing concentrations of E2 for 24 hours, followed by 0.01 nM E2 plus
increasing concentrations of ICI-182,780 for an additional 24 hours, luciferase activities were determined. All values represent the mean ±
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Page 9 of 11the occurrence of musculoskeletal pain in subjects with
variant SNP genotypes who have estrogen synthesis
blocked with AIs.
Discussion
The use of adjuvant AI therapy to treat ER-positive
breast cancer patients represents a major advance in the
treatment of that disease [26]. A recent report demon-
strating that an AI (exemestane) was highly efficacious
in preventing breast cancer highlights the importance of
understanding mechanisms responsible for the muscu-
loskeletal side effects of AI therapy [27]. These side
effects limit patient adherence to therapy with this
important class of drugs for either breast cancer treat-
ment or prevention. Equally important, however, may be
the fact that AI therapy represents a medically-indicated
form of pharmacologic estrogen deprivation that might
provide a window on mechanisms by which estrogen
withdrawal can cause musculoskeletal symptoms. Our
GWAS performed with DNA samples from patients
enrolled in the MA.27 clinical trial identified four SNPs
on chromosome 14 near the 3’ end of TCL1A that were
associated with increased risk for musculoskeletal
adverse events in women receiving adjuvant AI therapy
for the treatment of ER-positive breast cancer [6]. In the
present study, we pursued those observations and linked
E2-dependent induction of TCL1A to the expression of
a series of cytokines and cytokine receptors, including
IL-17RA, IL-17, IL-12RB2, IL-12 and IL-1R2, with SNP-
dependent variation in this induction (Figure 1).
Obviously, results obtained for other cell lines might
identify additional or different cytokines/cytokine recep-
tors, but the purpose of this study was to take the first
step in the elucidation of a novel pathway for estrogen-
dependent, TCL1A SNP-dependent regulation of cyto-
kine and cytokine receptor expression. Our results also
demonstrated a relationship between estrogen and SNP-
dependent variation in TCL1A expression and NF-B
transcriptional activity (Figure 6).
TCL1A expression is associated with CD4
+ and CD8
+
T-cell activation through the phosphoinositide 3-kinase/
Akt signaling pathway [28], and TCL1A enhances Akt
kinase activity [29]. However, there have been no pre-
vious reports of the regulation of TCL1A by estrogens
or of an association of TCL1A expression with cytokine
or cytokine receptor expression. A recent study did
report that another member of the TCL1 gene family,
TCL1B, is E2-inducible because of an ERE located near
the 3’ end of that gene [30]. The SNP with the lowest P
value in our GWAS, rs11849538, created an ERE near
the 3’ terminus of TCL1A, and cell lines that carried the
variant SNP genotype displayed increased TCL1A
expression after estrogen exposure (see Figures 1 and
6A).
In the present study, we found that increased expres-
sion of TCL1A upregulated IL-17RA expression and
downregulated the expression of IL-17, IL-12, IL-12RB2
and IL-1R2 (Figure 1). IL-17 has been reported not only
to drive the T-helper type 17 immune pathway, but also
to regulate the T-helper type 1 pathway by decreasing
IL-12 and IL-12RB2 subunit expression, especially in
patients with rheumatoid arthritis [31]. The E2-depen-
dent regulation of cytokine and cytokine receptor
expression that is mediated by TCL1A might help
explain the association of TCL1A with musculoskeletal
symptoms in patients treated with AIs. TCL1A can also
influence NF-B transcriptional activity (Figure 6), sug-
gesting that, after estrogen withdrawal, increased NF-B
activity might contribute to AI-induced musculoskeletal
pain. We also showed that cell lines containing variant
chromosome-14 SNP genotypes had significantly ele-
vated TCL1A expression aftere x p o s u r et oi n c r e a s i n g
concentrations of estrogen (Figures 1 and 6A). After ER
blockade with ICI-182,780, however, TCL1A expression
dropped precipitously in LCLs with variant SNPs, while
it was elevated in cells with the WT SNP genotypes
(Figure 6A). Conversely, NF-B transcriptional activity
increased after ER blockade in cells carrying variant
SNP genotypes (Figure 6B).
Conclusions
In summary, this series of experiments - studies that
began with a GWAS performed using DNA from women
receiving AIs to treat breast cancer - may provide insight
into mechanisms that relate AI-dependent estrogen with-
drawal to musculoskeletal symptoms. AI therapy is
designed to result in a striking decrease in estrogen
synthesis and in decreased circulating estrogen levels [6].
As a result, treatment with AIs represents medically-indi-
cated, pharmacologic estrogen deprivation - a therapeutic
maneuver that might provide insight into the possible
role of decreased circulating estrogens in musculoskeletal
pathophysiology.
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